Interpretation of lipoprotein-associated phospholipase A2 levels is influenced by cardiac disease, comorbidities, extension of atherosclerosis and treatments

International Journal of Cardiology

Volumn 168, Issue 1, 2013, Pages 132-138

  Charniot, J C ^a,b   Khani Bittar, R ^b,c   Albertini, J P ^a   Giral, P ^b,c   Cherfils, C ^b   Cosson, C ^d,e   Guillerm, E ^b   Leprince, P ^b   Gandjbakhch, I ^b   Bonnefont Rousselot, D ^b,e  

^a AVICENNE HOSPITAL   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d BICÊTRE HOSPITAL   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Comorbidities; Lp PLA2; Treatments

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; APOLIPOPROTEIN B; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGE; ANGIOCARDIOGRAPHY; AORTA ANEURYSM; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CARDIOMYOPATHY; CAROTID ARTERY DISEASE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE SEVERITY; DYSLIPIDEMIA; ECHOCARDIOGRAPHY; ECHOGRAPHY; ENZYME BLOOD LEVEL; FEMALE; GENDER; HEART DISEASE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; INFECTION; MAJOR CLINICAL STUDY; MALE; NEW YORK HEART ASSOCIATION CLASS; PRIORITY JOURNAL; SEPSIS; SMOKING; VALVULAR HEART DISEASE;

COMORBIDITIES; LP-PLA2; TREATMENTS;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADULT; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; COHORT STUDIES; COMORBIDITY; FEMALE; HEART DISEASES; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84883821592     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.09.054     Document Type: Article

References (37)

1. R. Ross Atherosclerosis - an inflammatory disease N Engl J Med 340 1999 115 126
2. H.S. Weintraub Identifying the vulnerable patient with rupture-prone plaque Am J Cardiol 101 2008 3F 10F
3. K. Sudhir Clinical review: lipoprotein-associated phospholipase A2, a novel inflammatory biomarker and independent risk predictor for cardiovascular disease J Clin Endocrinol Metab 90 2005 3100 3105
4. C.J. Packard, D.S. O'Reilly, and M.J. Caslake Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group N Engl J Med 343 2000 1148 1155
5. C.M. Ballantyne, R.C. Hoogeveen, and H. Bang Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study Circulation 109 2004 837 842
6. The Lp-PLA2 Studies collaboration Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke and mortality Lancet 375 2010 1536 1544
7. M.J. Caslake, C.J. Packard, and K.E. Suckling Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease Atherosclerosis 150 2000 413 419
8. L.C. van Vark, I. Kardys, and G.S. Bleumink Lipoprotein-associated phospholipase A2 activity and risk of heart failure: the Rotterdam study Eur Heart J 27 2006 2346 2352
9. Y. Gerber, S.M. Dunlay, and A.S. Jaffe Plasma lipoprotein-associated phospholipase A2 levels in heart failure: association with mortality in the community Atherosclerosis 203 2009 593 598
10. T. Suzuki, C. Solomon, and N.S. Jenny Lipoprotein-associated phospholipase A(2) and risk of congestive heart failure in older adults: the Cardiovascular Health Study Circ Heart Fail 2 2009 429 436
11. P.B. Gorelick Lipoprotein-associated phospholipase A2 and risk of stroke Am J Cardiol 101 2008 34F 40F
12. C. Iribarren, M.D. Gross, and J.A. Darbinian Association of lipoprotein-associated phospholipase A2 mass and activity with calcified coronary plaque in young adults: the CARDIA study Arterioscler Thromb Vasc Biol 25 2005 216 221
13. I. Kardys, H.H. Oei, and A. Hofman Lipoprotein-associated phospholipase A2 and coronary calcification. The Rotterdam Coronary Calcification Study Atherosclerosis 191 2007 377 383
14. E.S. Brilakis, J.P. McConnell, and R.J. Lennon Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up Eur Heart J 26 2005 137 144
15. I. Kardys, H.H. Oei, and I.M. van der Meer Lipoprotein-associated phospholipase A2 and measures of extracoronary atherosclerosis: the Rotterdam Study Arterioscler Thromb Vasc Biol 26 2006 631 636
16. E. Anuurad, Z. Ozturk, and B. Enkhmaa Association of lipoprotein- associated phospholipase A2 with coronary artery disease in African-Americans and Caucasians J Clin Endocrinol Metab 95 2010 2376 2383
17. M. Jessup, and S. Brozena Heart failure N Engl J Med 348 2003 2007 2018
18. A. Yndestad, J.K. Damås, and E. Oie Systemic inflammation in heart failure-the whys and wherefores Heart Fail Rev 11 2006 83 92
19. H. Hirota, M. Izumi, and T. Hamaguchi Circulating interleukin-6 family cytokines and their receptors in patients with congestive heart failure Heart Vessels 19 2004 237 241
20. I.S. Anand, R. Latini, and V.G. Florea C-reactive protein in heart failure: prognostic value and the effect of valsartan Circulation 112 2005 1428 1434
21. S.D. Anker, and S. von Haehling Inflammatory mediators in chronic heart failure: an overview Heart 90 2004 464 470
22. J.C. Charniot, R. Khani-Bittar, and J.P. Albertini Serial lipoprotein-associated phospholipase A2 assays: prognostic role in patients with cardiogenic shock without acute coronary syndrome Arch Cardiovasc Dis 2 2010 54 [Suppl.]
23. N. Unno, T. Nakamura, and H. Mitsuoka Association of a G994 ->T missense mutation in the plasma platelet-activating factor acetylhydrolase gene with risk of abdominal aortic aneurysm in Japanese Ann Surg 235 2002 297 302
24. T. Freestone, R.J. Turner, and A. Coady Inflammation and matrix metalloproteinases in the enlarging abdominal aortic aneurysm Arterioscler Thromb Vasc Biol 15 1995 1145 1151
25. A.E. Koch, G.K. Haines, and R.J. Rizzo Human abdominal aortic aneurysms. Immunophenotypic analysis suggesting an immune-mediated response Am J Pathol 137 1990 1199 1213
26. S. Endo, K. Inada, and H. Yamashita Platelet-activating factor (PAF) acetylhydrolase activity, type II phospholipase A2, and cytokine levels in patients with sepsis Res Commun Chem Pathol Pharmacol 83 1994 289 295
27. T. Takakuwa, S. Endo, and H. Nakae PAF acetylhydrolase and arachidonic acid metabolite levels in patients with sepsis Res Commun Chem Pathol Pharmacol 84 1994 283 290
28. M. van der Giet, M. Tölle, D. Pratico, V. Lufft, M. Schuchardt, M.P. Hörl, W. Zidek, and U.J. Tietge Increased type IIA secretory phospholipase A(2) expression contributes to oxidative stress in end-stage renal disease J Mol Med 88 2010 75 83
29. V.G. Saougos, A.P. Tambaki, and M. Kalogirou Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2 Arterioscler Thromb Vasc Biol 27 2007 2236 2243
30. E.J. Schaefer, J.R. McNamara, and B.F. Asztalos Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A2 in patients with coronary heart disease versus control subjects Am J Cardiol 95 2005 1025 1032
31. B. Zhang, P. Fan, and E. Shimoji Modulating effects of cholesterol feeding and simvastatin treatment on platelet-activating factor acetylhydrolase activity and lysophosphatidylcholine concentration Atherosclerosis 186 2006 291 301
32. J.B. Muhlestein, H.T. May, and J.R. Jensen The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study J Am Coll Cardiol 48 2006 396 401
33. S. Heeneman, J.C. Sluimer, and M.J. Daemen Angiotensin-converting enzyme and vascular remodeling Circ Res 101 2007 441 454
34. S. Hoshida, J. Kato, and M. Nishino Increased angiotensin-converting enzyme activity in coronary artery specimens from patients with acute coronary syndrome Circulation 103 2001 630 633
35. T. Hayek, J. Attias, and J. Smith Antiatherosclerotic and antioxidative effects of captopril in apolipoprotein E-deficient mice J Cardiovasc Pharmacol 31 1998 540 544
36. T. Hayek, J. Attias, and R. Coleman The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein E deficient mice Cardiovasc Res 44 1999 579 587
37. A. Radaelli, C. Loardi, and M. Cazzaniga Inflammatory activation during coronary artery surgery and its dose-dependent modulation by statin/ACE-inhibitor combination Arterioscler Thromb Vasc Biol 27 2007 2750 2755